Candriam SCA’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-315,832
| Closed | -$12.4M | – | 703 |
|
|
2023
Q2 | $12.4M | Sell |
315,832
-615,098
| -66% | -$21.7M | 0.09% | 218 |
|
|
2023
Q1 | $20.8M | Sell |
930,930
-204,902
| -18% | -$4.49M | 0.14% | 162 |
|
|
2022
Q4 | $24.3M | Buy |
1,135,832
+533,000
| +88% | +$11.4M | 0.16% | 147 |
|
|
2022
Q3 | $10.8M | Sell |
602,832
-863,739
| -59% | -$11.3M | 0.08% | 253 |
|
|
2022
Q2 | $14.1M | Buy |
1,466,571
+485,620
| +50% | +$6.1M | 0.12% | 178 |
|
|
2022
Q1 | $16.5M | Sell |
980,951
-234,321
| -19% | -$3.46M | 0.11% | 191 |
|
|
2021
Q4 | $20.3M | Hold |
1,215,272
| – | – | 0.13% | 176 |
|
|
2021
Q3 | $19.7M | Buy |
1,215,272
+539,697
| +80% | +$5.87M | 0.13% | 177 |
|
|
2021
Q2 | $4.26M | Buy |
+675,575
| New | +$4.36M | 0.03% | 439 |
|
|
2016
Q4 | – | Sell |
-47,500
| Closed | -$2.19M | – | 698 |
|
|
2016
Q3 | $2.19M | Sell |
47,500
-34,500
| -42% | -$1.95M | 0.05% | 340 |
|
|
2016
Q2 | $4.18M | Sell |
82,000
-19,000
| -19% | -$944K | 0.11% | 209 |
|
|
2016
Q1 | $4.25M | Sell |
101,000
-11,500
| -10% | -$586K | 0.11% | 217 |
|
|
2015
Q4 | $8.84M | Buy |
112,500
+39,000
| +53% | +$2.26M | 0.24% | 113 |
|
|
2015
Q3 | $2.98M | Sell |
73,500
-11,500
| -14% | -$609K | 0.07% | 280 |
|
|
2015
Q2 | $4.42M | Sell |
85,000
-51,000
| -38% | -$2.54M | 0.09% | 255 |
|
|
2015
Q1 | $6.33M | Hold |
136,000
| – | – | 0.13% | 211 |
|
|
2014
Q4 | $6.1M | Buy |
+136,000
| New | +$5.71M | 0.13% | 202 |
|
Candriam SCA's ISEE Position: Q3 2023 in Review
Candriam SCA sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 315,832 shares — an estimated $12.4M sold.
Candriam SCA first reported a position in ISEE in Q4 2014 and held it in 17 quarters. The position peaked at $24.3M in Q4 2022. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- Candriam SCA reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Candriam SCA sold 315,832 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $12.4M.
- Candriam SCA first reported a position in IVERIC bio, Inc. Common Stock in Q4 2014 and held it in 17 quarters.
- Candriam SCA's IVERIC bio, Inc. Common Stock position peaked at $24.3M in Q4 2022.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on Candriam SCA's 13F filing for Q3 2023, filed 13 Nov 2023.